Xizang Haisco Pharmaceutical Group Co Ltd Financial Flexibility Index
Xizang Haisco Pharmaceutical Group Co Ltd financial flexibility index. Xizang Haisco Pharmaceutical Group Co Ltd (002653) has a Financial Flexibility Index of 0.04x as of September 2025. Free cash flow of CN¥112.14 Million (operating CF CN¥39.68 Million minus capex CN¥72.46 Million) represents 0% of total liabilities (CN¥2.99 Billion). Explore Xizang Haisco Pharmaceutical Group Co Lt (002653) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)
Financial flexibility index of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025. Historical Financial Flexibility Index trend for Xizang Haisco Pharmaceutical Group Co Ltd across 18 annual periods. Check 002653 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Xizang Haisco Pharmaceutical Group Co Ltd Financial Flexibility Index by Year (2008–2025)
Xizang Haisco Pharmaceutical Group Co Ltd financial flexibility index by year from 2008 to 2025. Year-by-year free cash flow to debt coverage for Xizang Haisco Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see 002653 operating cash flow.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.41x | CN¥1.12 Billion | CN¥786.00 Million | CN¥2.72 Billion | ▲ +20.8% |
| 2024 | 0.34x | CN¥882.70 Million | CN¥442.05 Million | CN¥2.60 Billion | ▲ +0.4% |
| 2023 | 0.34x | CN¥840.59 Million | CN¥449.58 Million | CN¥2.48 Billion | ▲ +24.2% |
| 2022 | 0.27x | CN¥794.71 Million | CN¥94.55 Million | CN¥2.91 Billion | ▼ -23.0% |
| 2021 | 0.35x | CN¥738.74 Million | CN¥35.80 Million | CN¥2.09 Billion | ▼ -5.9% |
| 2020 | 0.38x | CN¥807.93 Million | CN¥206.21 Million | CN¥2.15 Billion | ▼ -25.7% |
| 2019 | 0.51x | CN¥1.35 Billion | CN¥764.26 Million | CN¥2.66 Billion | ▲ +45.7% |
| 2018 | 0.35x | CN¥824.59 Million | CN¥472.61 Million | CN¥2.37 Billion | ▼ -5.3% |
| 2017 | 0.37x | CN¥785.07 Million | CN¥391.81 Million | CN¥2.14 Billion | ▼ -10.9% |
| 2016 | 0.41x | CN¥617.44 Million | CN¥409.20 Million | CN¥1.50 Billion | ▼ -39.3% |
| 2015 | 0.68x | CN¥726.70 Million | CN¥443.03 Million | CN¥1.07 Billion | ▼ -29.4% |
| 2014 | 0.96x | CN¥737.43 Million | CN¥502.57 Million | CN¥767.55 Million | ▼ -30.4% |
| 2013 | 1.38x | CN¥732.40 Million | CN¥568.41 Million | CN¥530.24 Million | ▼ -44.2% |
| 2012 | 2.47x | CN¥590.05 Million | CN¥464.75 Million | CN¥238.49 Million | ▼ -24.9% |
| 2011 | 3.29x | CN¥378.52 Million | CN¥260.79 Million | CN¥114.95 Million | ▲ +29.9% |
| 2010 | 2.54x | CN¥448.33 Million | CN¥367.38 Million | CN¥176.79 Million | ▲ +38.5% |
| 2009 | 1.83x | CN¥392.22 Million | CN¥368.21 Million | CN¥214.22 Million | ▲ +92.7% |
| 2008 | 0.95x | CN¥131.82 Million | CN¥94.45 Million | CN¥138.73 Million | — |